The European signal first: a recommendation, not yet an approval
On 24 July 2026 the EMA's human-medicines committee (CHMP) adopted a positive opinion recommending marketing authorization of Gilead's Trodelvy together with Keytruda in first-line, PD-(L)1-positive metastatic triple-negative breast cancer.1 Gilead's release frames this as a second first-line approval that would make Trodelvy a backbone therapy across PD-L1 status in the European Union.1 A CHMP opinion is a step in the process, not the final authorization. The oncologist quoted in the release, Evandro de Azambuja, said as much: “If authorized, Trodelvy p” is the point where the dossier's excerpt of his quote ends, and it is cut off mid-sentence, so we do not complete it.1 His full statement is, in the dossier's wording, that patients with this cancer need effective options “as early as possible in the course of their disease.”1
A reliability note applies to this source. Our measurement of this wire feed found that 56% of 4,957 checked claims held up.1 Company press releases are a starting point, not a verdict.
Europe also features on the device side. Novocure, which datelines from Baar, Switzerland, reported second-quarter 2026 net revenues of $184 million, up 16% year over year, with 18% global growth in active patients.2 It also received a CE Mark for Optune Pax in locally advanced pancreatic cancer, with Germany the first EU market to launch and more than 280 active patients on Optune Pax as of 30 June 2026.2 Frank Leonard said: “This was our strongest quarter to date, with record net revenues and active patients on therapy.”2
What a late-stage bet costs: Summit's checked numbers
The most consequential US regulatory date in this story is 14 November 2026, the FDA goal date for Summit Therapeutics' Biologics License Application for ivonescimab, which is based on the HARMONi trial.4 Our dossier contains nothing on an EU filing for ivonescimab, so we will not guess at one. Summit matters to European investors mainly as a case study in what a pre-revenue, late-stage oncology programme consumes.
The figures below come from SEC filings and have been checked against that source of truth.3 Summit reported zero revenue in both FY2023 and FY2024.3 Its net loss was $614.9 million in FY2023, narrowed to $221.3 million in FY2024, then widened sharply to $1,079.6 million in FY2025.3 That FY2025 loss is about 4.8 times the $225.3 million in cash the company held at the end of that year, which gives a sense of the scale.3 Loss per share went from −$0.99 (FY2023) to −$0.31 (FY2024) to −$1.44 (FY2025).3
Cash actually leaving the business tells a steadier story. Operating cash outflow was $76.8 million in FY2023, $142.1 million in FY2024 and $322.9 million in FY2025, more than double the prior year.3 Capital expenditure stayed tiny by comparison: $128,000, $139,000 and $657,000 over the same three years.3 For FY2023, R&D expense was $59.5 million and operating loss $609.7 million; FY2024's operating loss was $226.0 million.3 The dossier does not break down what drove the gap between R&D expense and the much larger FY2023 operating loss, so we do not speculate.
The cash balance moves in large steps. It was $42.1 million at Q2 2023 and $23.8 million at Q3 2023.3 In 2024 it was $61.3 million at Q1, $28.4 million at Q2 and $93.8 million at Q3, ending the year at $104.9 million.3 In 2025 it was $211.5 million at Q1, $297.9 million at Q2 and $238.6 million at Q3, ending the year at $225.3 million.3 It then fell to $106.5 million at Q1 2026 and stood at $419.4 million at Q2 2026.3 The dossier does not say what produced the jump between those last two readings. Our analysis is that this is a company whose balance sheet depends on outside funding rounds around its regulatory milestones. That reading is Via News's inference from the pattern, not a statement from the company.
Other data points on the calendar
Moderna and Merck plan to present detailed intismeran results at ESMO on 24 October and to engage with regulators about potential filings.5 In multiple myeloma, the EXCALIBER-RRMM Phase 3 reported a median progression-free survival of 42 months for ZDd against 20 months for DVd (hazard ratio 0.49, p<0.000001), a 51% reduction in the risk of progression or death, with a median follow-up of 23 months.6 The follow-up is relatively short, so those medians will keep maturing. On 9 October the FDA approved Tecentriq in adjuvant stage III dMMR colon cancer, the twelfth US indication for the drug.7
Telix dosed the first patient in LUTEON, described as the first Phase 3 study of a CAIX-targeted radiopharmaceutical therapy in clear cell renal cell carcinoma.8 Aviral Singh said outcomes “remain poor for many patients.”8 This source scores lowest on reliability: only 31% of 2,928 checked claims held up, so treat its framing with extra care.8
AI-designed biologics: promising language, weak verification
An MIT Technology Review piece, in which Puja Sapra describes AstraZeneca's approach, sets out the ‘lab of the future’ vision. In her words: “Where a self-driving car uses sensors and models to navigate its environment, this system uses AI to make predictions, robotic systems to execute experiments, and instruments to generate data.”9 She names the company's edge as data: “Data is our differentiator.”9 She also concedes the hard part: “One of the hardest problems in de novo design is predicting whether a computationally generated molecule will be safe in the human body.”9 Human oversight, she says, “remains at the heart of this approach.”9
Readers should weigh this source with care. Our measurement found that none of the 11 checked claims from this document held up (0%).9 That does not mean the quotes were misattributed. The statements are verbatim and attributed to the speaker. It means the claims are aspirations and company positioning, not verified results. Our entity graph links AstraZeneca to the FTSE 100 and to ENHERTU (developed jointly with Daiichi Sankyo) and HER2, but it supplies no evidence that AI-designed molecules have reached the clinic.10
Consolidation: the Option Care take-private
On 6 October McKesson and Clayton, Dubilier & Rice announced a take-private acquisition of Option Care Health at $32.05 per share, a 37% premium to the previous close, valuing the company at $5.8 billion including debt.11 CD&R would own 51% and McKesson 49%.11 Option Care is headquartered in Bannockburn, Illinois, and the dossier shows no European operations.10 The dossier also holds no index-weighting data, so we cannot tell you whether your fund owns it. A take-private pays existing shareholders and then removes the company from public markets, so the deal matters to European readers as a signal of private-equity appetite for care delivery.
At the other end of the cost spectrum, ADC Therapeutics SA announced a workforce reduction “projected to deliver $10 million in annualised cost savings” and said it “maintains a cash runway into 2028.”12 That source scores 46% on reliability across 520 checked claims.12 Talent is moving too: Everest Medicines hired two former Moderna cancer-vaccine and translational leaders, Lakshmi Srinivasan and Brandon Coder, on 9 October.13
What to watch
- Whether the European Commission follows the CHMP's Trodelvy opinion with a formal authorization.
- 24 October: the ESMO intismeran presentation and any signal about regulatory filings.
- 14 November: the ivonescimab FDA decision, and whether Summit's next filings show cash and burn moving together.
- Whether the Option Care deal closes on the stated terms.
- Evidence, not language, that AI-designed biologics can pass the safety test Sapra herself calls one of the hardest problems.
